Lack of benefit of early awareness to age-related macular degeneration

Eye

Volumn 22, Issue 6, 2008, Pages 777-781

  Cervantes Castaneda R A ^a   Banin, E ^a   Hemo, I ^a   Shpigel, M ^a   Averbukh, E ^a   Chowers, I ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

VERTEPORFIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; EARLY DIAGNOSIS; FAMILY HISTORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETROSPECTIVE STUDY; SCREENING TEST; SMOKING; STATISTICAL SIGNIFICANCE; VISUAL ACUITY;

EID: 45449103298     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6702691     Document Type: Article

References (23)

1. Olsen TW, Feng X, Kasper TJ, Rath PP, Steuer ER. Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. Ophthalmology 2004; 111: 250-255.
2. Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, Guyer DP, Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-2816.
3. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001; 119: 198-207.
4. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331-335.
5. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-372.
6. Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 2003; 136: 407-418.
7. Grey RH, Bird AC, Chisholm IH. Senile disciform macular degeneration: features indicating suitability for photocoagulation. Br J Ophthalmol 1979; 63: 85-89.
8. Bressler NM. Early detection and treatment of neovascular age-related macular degeneration. J Am Board Fam Pract 2002; 15: 142-152.
9. Preferred practice pattern: Age related macular degeneration. American Academy of Ophthalmology: San Francisco, USA, 2003.
10. A randomized placebo-controlled clinical trial of high-dose supplementation with vitamins C and E beta carotenezinc for age-related macular degeneration vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119: 1417-1436.
11. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration other causes: Update. Retina 2005; 25: 119-134.
12. Lee PP, Feldman ZW, Ostermann J, Brown DS, Sloan FA. Longitudinal rates of annual eye examinations of persons with diabetes and chronic eye diseases. Ophthalmology 2003; 110: 1952-1959.
13. Sloan FA, Brown DS, Carlisle ES, Picone GA, Lee PP. Monitoring visual status: Why patients do or do not comply with practice guidelines. Health Serv Res 2004; 39: 1429-1448.
14. Klein ML, Jorizzo PA, Watzke RC. Growth features of choroidal neovascular membranes in age-related macular degeneration. Ophthalmology 1989; 96: 1416-1419.
15. Vander JF, Morgan CM, Schatz H. Growth rate of subretinal neovascularization in age-related macular degeneration. Ophthalmology 1989; 96: 1422-1426; discussion 6-9.
16. Fine SL. Early detection of extrafoveal neovascular membranes by daily central field evaluation. Ophthalmology 1985; 92: 603-609.
17. Loewenstein A, Malach R, Goldstein M, Leibovitch I, Barak A, Baruch E et al. Replacing the Amsler grid: A new method for monitoring patients with age-related macular degeneration. Ophthalmology 2003; 110: 966-970.
18. Roy MS. Vision loss without Amsler grid abnormalities in macular subretinal neovascularization. Ophthalmologica 1985; 191: 215-217.
19. Achard OA, Safran AB, Duret FC, Ragama E. Role of the completion phenomenon in the evaluation of Amsler grid results. Am J Ophthalmol 1995; 120: 322-329.
20. Zaidi FH, Cheong-Leen R, Gair EJ, Weir R, Sharkawi E, Lee N et al. The Amsler chart is of doubtful value in retinal screening for early laser therapy of subretinal membranes. The West London Survey. Eye 2004; 18: 503-508.
21. Arden GB, Wolf JE. Colour vision testing as an aid to diagnosis and management of age related maculopathy. Br J Ophthalmol 2004; 88 1180-1185.
22. Fink W, Sadun AA. Three-dimensional computer-automated threshold Amsler grid test. J Biomed Opt 2004; 9: 149-153.
23. Goldstein M, Loewenstein A, Barak A, Pollack A, Bukelman A, Katz H et al. Results of a multicenter clinical trial to evaluate the preferential hyperacuity perimeter for detection of age-related macular degeneration. Retina 2005; 25: 296-303.